25-Hydroxyvitamin D – Should labs be measuring it?

Alison Avenell, Mark J Bolland, Andrew Grey

Research output: Contribution to journalEditorial

3 Citations (Scopus)

Abstract

Perception of vitamin D supplementation as a panacea for good health continues. Media coverage proclaims widespread vitamin D deficiency, with supplementation needed to prevent disease,1 despite most research covered being epidemiological association studies beset by confounding and reverse causality. Commercial interests promoting supplementation influence advocacy organizations and academia.2 However, high-quality evidence indicates that vitamin D supplementation does not improve musculoskeletal outcomes, other than preventing rickets and osteomalacia in high-risk groups.3,4 Effects on non-musculoskeletal outcomes, such as cancer, cardiovascular disease and mortality, are unconvincing.3,4 Nevertheless, vitamin D has become medicalized,5 driving demands for predominantly inappropriate measurement of 25-hydroxyvitamin D (25OHD), the metabolite best reflecting tissue stores.6–8 Most Scottish laboratories limit testing to one/year/patient, but >1% of the population have 25OHD measured annually (Karen Smith, personal communication). Between 2008 and 2014, 25OHD testing in English children in primary care rose from 43/100,000 to 768/100,000 with an estimated cost in 2014 of £1.69 million.7
Original languageEnglish
Pages (from-to)188-189
Number of pages2
JournalAnnals of Clinical Biochemistry
Volume56
Issue number2
Early online date27 Aug 2018
DOIs
Publication statusPublished - 1 Mar 2019

Fingerprint

Vitamin D
Osteomalacia
Rickets
Vitamin D Deficiency
Causality
Epidemiologic Studies
Primary Health Care
Testing
Cardiovascular Diseases
Metabolites
Communication
Organizations
Costs and Cost Analysis
Mortality
Health
Tissue
Research
Population
25-hydroxyvitamin D
Neoplasms

Keywords

  • Journal Article

Cite this

25-Hydroxyvitamin D – Should labs be measuring it? / Avenell, Alison; Bolland, Mark J; Grey, Andrew.

In: Annals of Clinical Biochemistry, Vol. 56, No. 2, 01.03.2019, p. 188-189.

Research output: Contribution to journalEditorial

Avenell, Alison ; Bolland, Mark J ; Grey, Andrew. / 25-Hydroxyvitamin D – Should labs be measuring it?. In: Annals of Clinical Biochemistry. 2019 ; Vol. 56, No. 2. pp. 188-189.
@article{e190d6a3368c46ad979f657cc9d4aaca,
title = "25-Hydroxyvitamin D – Should labs be measuring it?",
abstract = "Perception of vitamin D supplementation as a panacea for good health continues. Media coverage proclaims widespread vitamin D deficiency, with supplementation needed to prevent disease,1 despite most research covered being epidemiological association studies beset by confounding and reverse causality. Commercial interests promoting supplementation influence advocacy organizations and academia.2 However, high-quality evidence indicates that vitamin D supplementation does not improve musculoskeletal outcomes, other than preventing rickets and osteomalacia in high-risk groups.3,4 Effects on non-musculoskeletal outcomes, such as cancer, cardiovascular disease and mortality, are unconvincing.3,4 Nevertheless, vitamin D has become medicalized,5 driving demands for predominantly inappropriate measurement of 25-hydroxyvitamin D (25OHD), the metabolite best reflecting tissue stores.6–8 Most Scottish laboratories limit testing to one/year/patient, but >1{\%} of the population have 25OHD measured annually (Karen Smith, personal communication). Between 2008 and 2014, 25OHD testing in English children in primary care rose from 43/100,000 to 768/100,000 with an estimated cost in 2014 of £1.69 million.7",
keywords = "Journal Article",
author = "Alison Avenell and Bolland, {Mark J} and Andrew Grey",
note = "The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Health Services Research Unit is funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorate.",
year = "2019",
month = "3",
day = "1",
doi = "10.1177/0004563218796858",
language = "English",
volume = "56",
pages = "188--189",
journal = "Annals of Clinical Biochemistry",
issn = "0004-5632",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - 25-Hydroxyvitamin D – Should labs be measuring it?

AU - Avenell, Alison

AU - Bolland, Mark J

AU - Grey, Andrew

N1 - The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Health Services Research Unit is funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorate.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Perception of vitamin D supplementation as a panacea for good health continues. Media coverage proclaims widespread vitamin D deficiency, with supplementation needed to prevent disease,1 despite most research covered being epidemiological association studies beset by confounding and reverse causality. Commercial interests promoting supplementation influence advocacy organizations and academia.2 However, high-quality evidence indicates that vitamin D supplementation does not improve musculoskeletal outcomes, other than preventing rickets and osteomalacia in high-risk groups.3,4 Effects on non-musculoskeletal outcomes, such as cancer, cardiovascular disease and mortality, are unconvincing.3,4 Nevertheless, vitamin D has become medicalized,5 driving demands for predominantly inappropriate measurement of 25-hydroxyvitamin D (25OHD), the metabolite best reflecting tissue stores.6–8 Most Scottish laboratories limit testing to one/year/patient, but >1% of the population have 25OHD measured annually (Karen Smith, personal communication). Between 2008 and 2014, 25OHD testing in English children in primary care rose from 43/100,000 to 768/100,000 with an estimated cost in 2014 of £1.69 million.7

AB - Perception of vitamin D supplementation as a panacea for good health continues. Media coverage proclaims widespread vitamin D deficiency, with supplementation needed to prevent disease,1 despite most research covered being epidemiological association studies beset by confounding and reverse causality. Commercial interests promoting supplementation influence advocacy organizations and academia.2 However, high-quality evidence indicates that vitamin D supplementation does not improve musculoskeletal outcomes, other than preventing rickets and osteomalacia in high-risk groups.3,4 Effects on non-musculoskeletal outcomes, such as cancer, cardiovascular disease and mortality, are unconvincing.3,4 Nevertheless, vitamin D has become medicalized,5 driving demands for predominantly inappropriate measurement of 25-hydroxyvitamin D (25OHD), the metabolite best reflecting tissue stores.6–8 Most Scottish laboratories limit testing to one/year/patient, but >1% of the population have 25OHD measured annually (Karen Smith, personal communication). Between 2008 and 2014, 25OHD testing in English children in primary care rose from 43/100,000 to 768/100,000 with an estimated cost in 2014 of £1.69 million.7

KW - Journal Article

UR - http://www.mendeley.com/research/25hydroxyvitamin-d-labs-measuring-it

U2 - 10.1177/0004563218796858

DO - 10.1177/0004563218796858

M3 - Editorial

VL - 56

SP - 188

EP - 189

JO - Annals of Clinical Biochemistry

JF - Annals of Clinical Biochemistry

SN - 0004-5632

IS - 2

ER -